VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2022 | The latest clinical research on ADCs in breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the latest clinical research on antibody-drug conjugates (ADCs) in breast cancer, including the BEGONIA (NCT03742102) trial, investigating the anti-TROP-2 ADC, datopotamab deruxtecan, with immunotherapy in the first-line setting for metastatic triple-negative breast cancer (TNBC). Dr Tarantino additionally mentions the Phase II Daisy (NCT04132960) trial, which aims to elucidate resistance mechanisms to trastuzumab deruxtecan in patients with varying levels of HER2 expression via biomarker analyses. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter